Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.

被引：1
|
作者：
Miller, Kurt
Cella, David
De Phung
Naidoo, Shevani
Holmstrom, Stefan
Ivanescu, Cristina
Skaltsa, Konstantina
机构：
[1] Charite, Dept Urol, Berlin, Germany
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Astellas Pharma Europe, Leiden, Netherlands
[4] Astellas Pharma, Chertsey, England
[5] Quintiles, Hoofddorp, Netherlands
[6] Quintiles, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5060
引用
收藏
页数：3
相关论文
共 50 条
  • [1] RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH NO PRIOR CHEMOTHERAPY: RESULTS FROM PREVAIL STUDY
    Beer, T. M.
    Ivanescu, C.
    Skaltsa, K.
    Naidoo, S.
    Phung, D.
    Tombal, B.
    VALUE IN HEALTH, 2016, 19 (03) : A158 - A158
  • [2] Relationship between quality of life and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients in ALSYMPCA.
    Nilsson, Sten
    Sartor, A. Oliver
    Vogelzang, Nicholas J.
    Coleman, Robert E.
    O'Sullivan, Joe M.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.
    Winquist, Eric
    Sridhar, Srikala S.
    Hubay, Stacey
    Assi, Hazem
    Berry, Scott R.
    Alloul, Karine
    Levesque, Eric
    Aucoin, Nathalie
    Czaykowski, Piotr
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Cella, D.
    VALUE IN HEALTH, 2015, 18 (07) : A335 - A336
  • [5] Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
    Cella, D.
    Ivanescu, C.
    Holmstrom, S.
    Bui, C. N.
    Spalding, J.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 179 - 185
  • [6] Impact of enzalutamide (ENZA) compared with bicalutamide (BIC) on quality of life (QoL) in men with metastatic castration-resistant prostate cancer (mCRPC): Results from the TERRAIN study
    Heidenreich, A.
    Chowdhury, S.
    Klotz, L.
    Siemens, D. R.
    Villers, A.
    Ivanescu, C.
    Holmstrom, S.
    Baron, B.
    Wang, F.
    Forer, D.
    Shore, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S495 - S495
  • [7] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts)
    Rubio-Novella, S.
    Montes, A.
    Paredero Perez, I.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Castro, E.
    Sanchez Hernandez, A.
    Olmos, D.
    Lorente Estelles, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S648 - S649
  • [9] Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, A. W.
    Tidwell, R. S.
    Surasi, D. S.
    Msaouel, P.
    Efstathiou, E.
    Zurita-Saavedra, A. J.
    Tu, S-M.
    McQuade, J. L.
    Fogelman, D.
    Starbuck, M. W.
    Subudhi, S. K.
    Corn, P.
    Pilie, P. G.
    Aparicio, A.
    Logothetis, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S538 - S538
  • [10] Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    Sternberg, Cora N.
    De Bono, Johann Sebastian
    Chi, Kim N.
    Fizazi, Karim
    Mulders, Peter
    Hirmand, Mohammad
    Forer, David
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345